By Mill Chart
Last update: Feb 14, 2024
Our stock screening tool has identified SANOFI-ADR (NASDAQ:SNY) as an undervalued gem with strong fundamentals. NASDAQ:SNY boasts decent financial health and profitability while maintaining an attractive price point. We'll break it down further.
ChartMill employs its own Valuation Rating system for all stocks. This score, ranging from 0 to 10, is determined by evaluating different valuation factors, including price to earnings and free cash flow, both in absolute terms and relative to the market and industry. NASDAQ:SNY has earned a 7 for valuation:
ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NASDAQ:SNY was assigned a score of 7 for profitability:
ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NASDAQ:SNY has earned a 5 out of 10:
ChartMill assigns a Growth Rating to each stock, ranging from 0 to 10. This rating is determined by analyzing different growth elements, including EPS and revenue growth, spanning both historical and future figures. In the case of NASDAQ:SNY, the assigned 4 reflects its growth potential:
More Decent Value stocks can be found in our Decent Value screener.
For an up to date full fundamental analysis you can check the fundamental report of SNY
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
SANOFI-ADR
NASDAQ:SNY (4/18/2024, 7:20:55 PM)
Premarket: 46.12 +0.73 (+1.61%)45.39
-0.72 (-1.56%)
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
Auddia stock is taking off on Monday with heavy trading of AUUD stock after the company received a new AI tech patent.
Apartment Income REIT stock is rising higher on Monday as investors in AIRC shares react to a deal to take the company private.
Sanofi layoffs are coming for the company's R&D employees and it makes major changes to how it handles development going forward.
With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential.
With certain sectors in the domestic market appearing overstretched, these global growth stocks may offer better opportunities.
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.